Delaware court refuses to enforce Fresenius/Akorn merger agreement
Credit: iStock.com/kontrast-fotodesign
A judge has ruled that healthcare company Fresenius was entitled to pull out of a planned $4.75 billion takeover of generic drugmaker Akorn, after finding that the target made false representations about the state of its data.
To read more
Subscribe to Global Data Review
Subscribe and start reading now
The one-stop information source and community touchpoint, with coverage from across the areas of
- Data protection
- Cybersecurity
- IP
- IT
- TMT
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10